Li CM - Search Results

1

Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.

Beltran PJ, Calzone FJ, Mitchell P, Chung YA, Cajulis E, Moody G, Belmontes B, Li CM, Vonderfecht S, Velculescu VE, Yang G, Qi J, Slamon DJ, Konecny GE. Beltran PJ, et al. Among authors: li cm. Clin Cancer Res. 2014 Jun 1;20(11):2947-58. doi: 10.1158/1078-0432.CCR-13-3448. Epub 2014 Apr 11. Clin Cancer Res. 2014. PMID: 24727326 Free PMC article.

2

AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys.

Goldstein RL, Goyos A, Li CM, Deegen P, Bogner P, Sternjak A, Thomas O, Klinger M, Wahl J, Friedrich M, Rattel B, Lamas E, Min X, Sudom A, Farshbaf M, Coxon A, Balazs M, Arvedson T. Goldstein RL, et al. Among authors: li cm. Blood Adv. 2020 Sep 8;4(17):4180-4194. doi: 10.1182/bloodadvances.2020002565. Blood Adv. 2020. PMID: 32886754 Free PMC article.

3

New variants in the Enpp1 and Ptpn6 genes cause low BMD, crystal-related arthropathy, and vascular calcification.

Babij P, Roudier M, Graves T, Han CY, Chhoa M, Li CM, Juan T, Morony S, Grisanti M, Li X, Yu L, Dwyer D, Lloyd DJ, Bass MB, Richards WG, Ebeling C, Amato J, Carlson G. Babij P, et al. Among authors: li x, li cm. J Bone Miner Res. 2009 Sep;24(9):1552-64. doi: 10.1359/jbmr.090417. J Bone Miner Res. 2009. PMID: 19419305 Free article.

4

Nonclinical Safety Assessment of AMG 553, an Investigational Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Acute Myeloid Leukemia.

Karbowski C, Goldstein R, Frank B, Kim K, Li CM, Homann O, Hensley K, Brooks B, Wang X, Yan Q, Hernandez R, Adams G, Boyle M, Arvedson T, Lebrec H. Karbowski C, et al. Among authors: li cm. Toxicol Sci. 2020 Sep 1;177(1):94-107. doi: 10.1093/toxsci/kfaa098. Toxicol Sci. 2020. PMID: 32589753 Free PMC article.

5

Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia.

Brauchle B, Goldstein RL, Karbowski CM, Henn A, Li CM, Bücklein VL, Krupka C, Boyle MC, Koppikar P, Haubner S, Wahl J, Dahlhoff C, Raum T, Rardin MJ, Sastri C, Rock DA, von Bergwelt-Baildon M, Frank B, Metzeler KH, Case R, Friedrich M, Balazs M, Spiekermann K, Coxon A, Subklewe M, Arvedson T. Brauchle B, et al. Among authors: li cm. Mol Cancer Ther. 2020 Sep;19(9):1875-1888. doi: 10.1158/1535-7163.MCT-19-1093. Epub 2020 Jun 9. Mol Cancer Ther. 2020. PMID: 32518207

6

Blinatumomab-induced T cell activation at single cell transcriptome resolution.

Huo Y, Sheng Z, Lu DR, Ellwanger DC, Li CM, Homann O, Wang S, Yin H, Ren R. Huo Y, et al. Among authors: li cm. BMC Genomics. 2021 Mar 1;22(1):145. doi: 10.1186/s12864-021-07435-2. BMC Genomics. 2021. PMID: 33648458 Free PMC article.

7

Autonomous IL-36R signaling in neutrophils activates potent antitumor effector functions.

Roy S, Fitzgerald K, Lalani A, Lai CW, Kim A, Kim J, Ou P, Mirsoian A, Liu X, Ramrakhiani A, Zhao H, Zhou H, Xu H, Meisen H, Li CM, Lugt BV, Thibault S, Tinberg CE, DeVoss J, Egen J, Wu LC, Noubade R. Roy S, et al. Among authors: li cm. J Clin Invest. 2023 Jun 15;133(12):e162088. doi: 10.1172/JCI162088. J Clin Invest. 2023. PMID: 37317970 Free PMC article.

8

Attenuated IL-2 muteins leverage the TCR signal to enhance regulatory T cell homeostasis and response in vivo.

Ma S, So M, Ghelani A, Srivas R, Sahoo A, Hall R, Liu W, Wu H, Yu S, Lu S, Song E, Cariaga T, Soto M, Zhou H, Li CM, Chaudhry A, Luo X, Sohn SJ. Ma S, et al. Among authors: li cm. Front Immunol. 2023 Sep 22;14:1257652. doi: 10.3389/fimmu.2023.1257652. eCollection 2023. Front Immunol. 2023. PMID: 37809101 Free PMC article.

9

Haploinsufficiency of the Insulin Receptor in the Presence of a Splice-Site Mutation in Ppp2r2a Results in a Novel Digenic Mouse Model of Type 2 Diabetes.

Goldsworthy M, Bai Y, Li CM, Ge H, Lamas E, Hilton H, Esapa CT, Baker D, Baron W, Juan T, Véniant MM, Lloyd DJ, Cox RD. Goldsworthy M, et al. Among authors: li cm. Diabetes. 2016 May;65(5):1434-46. doi: 10.2337/db15-1276. Epub 2016 Feb 11. Diabetes. 2016. PMID: 26868295 Free PMC article.

10

Defining the Threshold IL-2 Signal Required for Induction of Selective Treg Cell Responses Using Engineered IL-2 Muteins.

Ghelani A, Bates D, Conner K, Wu MZ, Lu J, Hu YL, Li CM, Chaudhry A, Sohn SJ. Ghelani A, et al. Among authors: li cm. Front Immunol. 2020 Jun 5;11:1106. doi: 10.3389/fimmu.2020.01106. eCollection 2020. Front Immunol. 2020. PMID: 32582190 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,195 results

Search Page

Filters